Fulan Wang1, Liangdan Tang1, Li Wang1, Xiaoyan Wang1, Jinyun Chen1, Xiaohua Liu1, Yao Gong2. 1. Department of Gynecology and Obstetrics, First Affiliated Hospital of Chongqing Medical University, Chongqing, China (all authors). 2. Department of Gynecology and Obstetrics, First Affiliated Hospital of Chongqing Medical University, Chongqing, China (all authors). Electronic address: yao_gong@hotmail.com.
Abstract
STUDY OBJECTIVE: To assess the quality of life (QoL) of women at 1 and 12 months after ultrasound-guided high-intensity focused ultrasound (USgHIFU) treatment as compared with laparoscopic myomectomy for treatment of symptomatic uterine myomas. DESIGN: Nonrandomized prospective clinical trial (Canadian Task Force classification II-2). SETTING: Urban university-based hospital in China. INTERVENTIONS: One hundred thirty premenopausal women underwent USgHIFU (n = 89) or laparoscopic myomectomy (n = 41) for treatment of symptomatic uterine myomas. MEASUREMENTS AND MAIN RESULTS: Eighty-three patients in the HIFU group and 39 in the surgical group were followed up at 1 and 12 months. QoL was assessed using the Medical Outcomes Study 36-Item Short-Form General Health Survey, which showed no significant differences between groups in any of the 8 subscales at the 12-month follow-up visit. Symptom score, willingness to recommend the treatment to a friend, hospital stay, and recovery period were compared between the 2 groups. In the HIFU group, hospital stay was shorter (mean [SD] 2.9 [1.5] days vs 6.2 [2.7] days; p <.001) and patients resumed normal activities sooner (4.5 [1.5] days vs 10.9 [3.8] days; p <.001). Significant clinical complications and adverse events after each treatment were documented and compared, and HIFU yielded significantly better results. CONCLUSIONS: Compared with laparoscopic myomectomy, HIFU treatment of symptomatic uterine myomas leads to comparable QoL and symptom improvement, fewer significant clinical complications and adverse events, shorter hospital stay, and faster recovery. Randomized studies with long-term follow-up are needed to reach definitive conclusions insofar as HIFU treatment of uterine myomas.
STUDY OBJECTIVE: To assess the quality of life (QoL) of women at 1 and 12 months after ultrasound-guided high-intensity focused ultrasound (USgHIFU) treatment as compared with laparoscopic myomectomy for treatment of symptomatic uterine myomas. DESIGN: Nonrandomized prospective clinical trial (Canadian Task Force classification II-2). SETTING: Urban university-based hospital in China. INTERVENTIONS: One hundred thirty premenopausal women underwent USgHIFU (n = 89) or laparoscopic myomectomy (n = 41) for treatment of symptomatic uterine myomas. MEASUREMENTS AND MAIN RESULTS: Eighty-three patients in the HIFU group and 39 in the surgical group were followed up at 1 and 12 months. QoL was assessed using the Medical Outcomes Study 36-Item Short-Form General Health Survey, which showed no significant differences between groups in any of the 8 subscales at the 12-month follow-up visit. Symptom score, willingness to recommend the treatment to a friend, hospital stay, and recovery period were compared between the 2 groups. In the HIFU group, hospital stay was shorter (mean [SD] 2.9 [1.5] days vs 6.2 [2.7] days; p <.001) and patients resumed normal activities sooner (4.5 [1.5] days vs 10.9 [3.8] days; p <.001). Significant clinical complications and adverse events after each treatment were documented and compared, and HIFU yielded significantly better results. CONCLUSIONS: Compared with laparoscopic myomectomy, HIFU treatment of symptomatic uterine myomas leads to comparable QoL and symptom improvement, fewer significant clinical complications and adverse events, shorter hospital stay, and faster recovery. Randomized studies with long-term follow-up are needed to reach definitive conclusions insofar as HIFU treatment of uterine myomas.
Authors: Julia Caroline Radosa; Christoph Georg Radosa; Russalina Mavrova; Stefan Wagenpfeil; Amr Hamza; Ralf Joukhadar; Sascha Baum; Maria Karsten; Ingolf Juhasz-Boess; Erich-Franz Solomayer; Marc Philipp Radosa Journal: PLoS One Date: 2016-11-29 Impact factor: 3.240
Authors: Lazzaro di Biase; Emma Falato; Maria Letizia Caminiti; Pasquale Maria Pecoraro; Flavia Narducci; Vincenzo Di Lazzaro Journal: Neurol Res Int Date: 2021-06-29